Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the second quarter of 2010. Nymox reported a net loss of $1,745,798, or $0.05 per share for the quarter and $3,015,348, or $0.10 per share for the six months ending June 30, 2010, compared to $1,220,152, or $0.04 per share for the quarter and $2,224,411, or $0.07 per share for the six months ending June 30, 2009. Net losses include stock compensation charges for the quarter of $245,245 in 2010 and $248,886 in 2009 and for the six months ending June 30 of $440,465 in 2010 and $558,536 in 2009. The increase of the net loss for the quarter and for the six months ending June 30, 2010 is mainly attributable to increased expenditures relating to the Phase 3 clinical trials for NX-1207. Product sales amounted to $104,550 for the quarter and $351,411 for the six months ending June 30, 2010, compared to $80,341 and $176,567 for the same periods in 2009. Sales of NicAlert/TobacAlert to new clients explains the increase in sales for the quarter and the six months ended June 30, 2010 compared to the same periods in 2009. The weighted average number of common shares outstanding for the six months ended June 30, 2010 was 31,627,450 compared to 30,412,501 for the same period in 2009.
Nymox Pharmaceutical Corporation is a biotechnology company engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. The Company's new drug for benign prostatic hyperplasia (BPH) is in Phase 3 development. Nymox has a number of drugs in development for other indications such as E. coli infection, Alzheimer's disease, oncology, and infectious disease. The Company offers NicAlert™ and TobacAlert™ tests for measuring tobacco product exposure, and AlzheimAlert ™, a test to aid in the diagnosis of Alzheimer's disease.
Cosmochemistry techniques shed light on potential new Alzheimer's disease biomarker